Mylvaganam Murugesapillai, Hansen Henrik C, Binnington Beth, Magnusson Göran, Nyholm Per-Georg, Lingwood Clifford A
Division of Infection, Immunity, Injury and Repair, Research Institute, Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada.
Biochem J. 2002 Dec 15;368(Pt 3):769-76. doi: 10.1042/BJ20020225.
Specific hydroxy groups of the terminal disaccharide unit of globotriaosyl ceramide (Gb(3)Cer) were identified from binding studies with deoxyGb(3)Cer and verotoxins (VTs) [Nyholm, Magnusson, Zheng, Norel, Binnington-Boyd and Lingwood (1996) Chem. Biol. 3, 263-275]. Four such hydroxy groups (2", 4", 6" and 6') were each substituted with an amino group and the corresponding deoxyamino globotrioses were conjugated to a ceramide-like aglycone which contained an adamantyl group instead of an acyl chain. Such aglycone modification significantly enhanced the water-solubility of the glycoconjugates [Mylvaganam and Lingwood (1999) Biochem. Biophys. Res. Commun. 257, 391-394]. The inhibitory potential of these soluble aminodeoxy conjugates on the binding of VT(1) to Gb(3)Cer immobilized on an ELISA plate was evaluated. Only the 2" and the 6' deoxyamino conjugates were effective inhibitors (IC(50) 10 microM); the 4" and 6" conjugates were ineffective up to 10 mM. To evaluate the importance of incorporating a rigid adamantyl hydrocarbon group into the ceramide aglycone, globotriaose was conjugated to a t- butylacetamido or an adamantaneacetamido aglycone. By similar ELISAs, only the adamantaneacetamido conjugate inhibited the binding of VT(1) to Gb(3)Cer. When deoxyamino conjugates were adsorbed to silica on TLC plates, only the 2" and 6" conjugates bound VT(1) and VT(2). By a similar TLC assay, acetamido derivatives of 2" and 6' deoxyamino conjugates showed less binding to VT(1) and VT(2). Neither the crystallographically determined structure of the VT(1)-globotriaose complex nor modelling studies fully explain the binding patterns shown by these deoxyamino glycoconjugates. Enhanced solvation of the ammonium group of the deoxyamino conjugate could enforce greater constraints in the binding interactions.
通过与脱氧Gb(3)Cer和志贺毒素(VTs)的结合研究,确定了球三糖神经酰胺(Gb(3)Cer)末端二糖单元的特定羟基[Nyholm, Magnusson, Zheng, Norel, Binnington-Boyd和Lingwood(1996年)《化学生物学》3, 263 - 275]。四个这样的羟基(2"、4"、6"和6')分别被氨基取代,相应的脱氧氨基球三糖与一种类似神经酰胺的苷元偶联,该苷元含有一个金刚烷基而不是酰基链。这种苷元修饰显著提高了糖缀合物的水溶性[Mylvaganam和Lingwood(1999年)《生物化学与生物物理研究通讯》257, 391 - 394]。评估了这些可溶性氨基脱氧缀合物对VT(1)与固定在酶联免疫吸附测定(ELISA)板上的Gb(3)Cer结合的抑制潜力。只有2"和6'脱氧氨基缀合物是有效的抑制剂(半数抑制浓度(IC(50))为10微摩尔);4"和6"缀合物在高达10毫摩尔时无效。为了评估在神经酰胺苷元中引入刚性金刚烷烃基的重要性,将球三糖与叔丁基乙酰胺或金刚烷乙酰胺苷元偶联。通过类似的ELISA,只有金刚烷乙酰胺缀合物抑制VT(1)与Gb(3)Cer的结合。当脱氧氨基缀合物吸附在薄层层析(TLC)板上的硅胶上时,只有2"和6"缀合物结合VT(1)和VT(2)。通过类似的TLC分析,2"和6'脱氧氨基缀合物的乙酰胺衍生物与VT(1)和VT(2)的结合较少。VT(1)-球三糖复合物的晶体结构测定和模型研究都不能完全解释这些脱氧氨基糖缀合物所显示的结合模式。脱氧氨基缀合物铵基团的增强溶剂化可能在结合相互作用中施加更大的限制。